Children with Down Syndrome (DS) up to the age of 4 years are at a 150-fold excess risk of developing myeloid leukemia (ML-DS). Approximately 4-5% of newborns with DS develop transient myeloproliferative disorder (TMD). Blast cell morphology and immunophenotype is similar in TMD and ML-DS. A mutation in the hematopoietic transcription factor GATA1 is present in almost all cases. Here we show that simple techniques detect GATA1 mutations in the largest series of TMD (n=134 -88%) and ML-DS (n=103 -85%) tested. Furthermore, no significant difference in the mutational spectrum between the two disorders was seen.
Introduction
Children with trisomy 21 (T21,Down Syndrome) have ~150-fold increased incidence of myeloid leukemia (ML-DS) leukaemia 1,2 . Incidence of Transient Myeloproliferative Disorder (TMD) is estimated at ~4-5% of DS neonates 1, 3 . ~20-30% of these neonates develop ML-DS by 4 years of age [4] [5] . Both diseases are characterised by a clonal population of blasts, with similar immunophenotype and morphology, in blood/bone marrow. However, TMD spontaneously regresses whereas ML-DS is stably transformed.
In addition to T21, blast cells in TMD and ML-DS carry acquired mutations in the hematopoietic transcription factor GATA1 [6] [7] [8] [9] [10] [11] [12] [13] [14] . These lead to expression of N-terminally truncated GATA1s protein. Mutations are detectable in disease, not remission 3, [6] [7] [8] [9] [10] [11] [12] [13] [14] . The majority of reported mutations are found in GATA1 exon 2 including insertions, deletions and point mutations. Where TMD progresses to ML-DS, the same GATA1 mutation is usually present in blasts of both, demonstrating their clonal relationship 5, 14 .
There is debate about whether the type of GATA1 mutation determines progression to ML-DS 9,15-17 . To examine this, we analyzed GATA1 mutations in 134 TMD and 103 ML-DS cases, the largest patient cohort reported to date. Of these 8 paired TMD and follow-up ML-DS samples were available. GATA1 mutations were detected in 226 (95%) patients. The lower limit blast percentage for successful detection of GATA1 mutations was 0.5%. There was no difference in types of mutation between TMD and ML-DS patients. Contrary to previous data 15 we did not detect specific GATA1 mutation types more commonly in ML-DS.
Therefore, the type of GATA1 mutation in our series is not prognostic of which TMD patients will progress to ML-DS.
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From 6 77%, point mutations 23%). 8 patients had paired TMD and follow-up ML-DS samples. The same mutation was present in both TMD and ML-DS for 7/8, similar to previous observations 12, 14 . Predicted consequence of mutations was similar for both TMD and ML-DS (Fig. 1C) . Most mutations inserted a premature termination codon (PTC) either by introducing a stop codon or frameshift. Mutations affecting the splice site at GATA1 exon 2 exon/intron boundary were next most frequent. In some cases (3 TMD and 3 DS-ML) where a point mutation occurred in intronic sequence, predicted consequence was unclear. They may occur in splice site regulatory elements and affect gene splicing 18 . In 13 TMD patients that progressed to ML-DS predicted consequences in the protein were similar.
Characterising the sequence of GATA1 mutations provides an opportunity to develop patient mutation-specific quantitative PCR analysis to monitor resolution of TMD, persistence/reemergence of GATA1 mutant clone leading to ML-DS and therapy response in ML-DS patients 13 . Direct sequencing of DNA from FACS-sorted blasts was successful in identifying sequence mutation in 19 patients where direct sequencing of DNA from unfractionated samples failed. In 20 cases it was necessary to subclone GATA1 PCR product to pinpoint mutation sequence.
A previous study divided GATA1 mutations in TMD and ML-DS into two classes based on levels of GATA1s protein expression 15 . Mutations affecting gene splicing, the start codon (1 st Met) or that introduced a PTC in the 3' end of exon 2 (PTC1-3') resulted in high GATA1s protein levels; whereas a PTC in the 5' end of exon 2 (PTC1-5') or in exon 3.1 (PTC-2) resulted in low GATA1s expression 15 . TMD patients with mutations predicted to result in low GATA1s protein expression were more likely to develop ML-DS as this type of mutation had significantly higher incidence in ML-DS 15 . We asked if this was true for our sample cohort.
No significant differences were found between numbers of samples in each of the mutation types when TMD and ML-DS were compared (Supplementary Similarly, we found no significant increase in predicted GATA1s low expressing mutations in ML-DS samples versus TMD (p = 0.5534; Table 1 ). In 12 TMD samples that progressed to ML-DS where we obtained a sequence mutation predicted to affect protein expression, equal numbers were predicted to result in high and low GATA1s protein expression (i.e. 6 of each).
GATA1s cDNA qPCR for 36 TMD and 20 ML-DS patient samples showed no significant differences in GATA1s mRNA expression in patients with PTC 1-3', Splice, PTC 1-5' or unknown effect mutations (Supplementary Figure 1) .
Cytogenetic data was available for 31 TMD and 68 ML-DS patients (Table 1) . In TMD neonates, there was no significant correlation between not progressing to ML-DS and presenting with T21 as the only cytogenetic abnormality (p = 0.2533) (Supplementary Table   2 ). Therefore, karyotype does not predict patients that will progress to ML-DS.
In conclusion, simple techniques detect GATA1 mutations in most TMD and ML-DS patients.
It is not possible to predict progression of TMD to ML-DS based on type of GATA1 mutation, at least in mainly Caucasian patients.
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C a n c e r G e n e t C y t o g e n e t Column 1 -unique patient identifier. Column 2 -diagnosis (TMD or ML-DS). Column 3 -blast count (% of total nucleated count). Column 4 -exon number containing the mutation as defined by WAVE analysis. Column 5 -mutation type. Point -point substitution; dupduplication of nucleotides; ins -insertion of nucleotides; del -deletion of nucleotides.
Column 6 -number of nucleotides changed in base pairs. 
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